Introduction: Fasting and postprandial plasma
INTRODUCTION
Type 2 diabetes is a progressive disease characterized by decreased insulin sensitivity and deteriorating beta-cell insulin secretion. 1 It has also been found that impaired incretin function due to a decrease in the levels and the insulinotropic effects of the incretin hormones could be an important factor. 2, 3 Intensive treatment to achieve good glycemic control, as assessed by glycosylated hemoglobin (HbA 1c ) levels, can significantly reduce the risk of type 2 diabetes complications. 4, 5 As HbA 1c is a measure of average fasting and postprandial plasma glucose (FPG, PPG) levels, 6 therapies that target both contributors are necessary to achieve optimal glycemic control.
7
The incretin hormones glucagon-like peptide 1 (GLP-1) and glucagon-dependent insulinotropic polypeptide (GIP) are released in the intestine shortly after nutrient ingestion, and are responsible for mediating the incretin effect (ie, the enhanced insulin secretion observed after oral glucose administration, compared with an isoglycemic intravenous challenge). 8,9 GLP-1 has been shown to be a physiological modulator of gastric motility, 10 and the inhibitory effect of exogenous GLP-1 on gastric emptying has been demonstrated in healthy subjects, 11, 12 as well as in patients with type 2 diabetes. 13, 14 GLP-1 has been shown to have diverse effects on gastrointestinal functions in humans, such as relaxation of the proximal stomach, inhibition of antroduodenal contractility, and stimulation of pyloric motility. 10, 12, 13, [15] [16] [17] [18] Precisely how GLP-1 mediates these effects on gastric emptying however (ie, centrally or peripherally mediated)
is not known, and further studies are required to elucidate such mechanisms.
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Exenatide 19 and liraglutide 20 share the ability to slow gastric emptying. However, this effect has yet to be shown with clinically relevant doses of liraglutide, and this was part of the aim of our study.
The physiological actions of GLP-1 are preserved in individuals with type 2 diabetes, 21, 22 giving this molecule great potential as a therapeutic agent. Unfortunately, native GLP-1 is rapidly degraded by the enzymes dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidase 
METHODS

Design of Study
This was a single-center, randomized, placebo- 
Assessments
To assess adherence to liraglutide injections, morning blood samples were collected at baseline All AUC values were calculated by the linear trapezoidal method and were log transformed prior to statistical analysis, except incremental AUC data, where the untransformed values were used for the analysis. C 0 , C 2 hours, and C max were obtained as the observed value at baseline, after 2 hours, and as the maximum value over 5 hours, respectively. In addition, an explorative statistical analysis of the association between glucose iAUC 0-1 h , and gastric emptying measured by log (paracetamol AUC 0-1 h ) was performed. All PD endpoints among subjects receiving liraglutide and subjects receiving placebo were compared by use of a two-sided test at a 5% significance level (ie, P<0.05). All safety data were evaluated by the use of summary statistics.
RESULTS
Subjects
Eighteen subjects were included in the study. All subjects were white and 78% (n=14) Most of the subjects (n=16; 89%) were on OAD monotherapy before commencing the trial.
One subject had measurable concentrations of liraglutide during treatment with placebo.
Therefore, data from the placebo treatment period of this subject were excluded.
Glucose
The absolute and baseline-corrected glucose time- (Table 1 ).
FPG
The difference in the starting point of the profiles in Figure 1 represents the effect of steady-state liraglutide doses of 0.6, 1.2, and 1.8 mg on FPG.
On average, this difference was 3-4 mmol/L lower with liraglutide than compared with placebo.
The statistical analysis confirmed a significant decrease in FPG levels at all three liraglutide dose levels when compared with placebo (P<0.001) (Table 1 ).
Insulin
C 0 was significantly higher with liraglutide than with placebo at all three doses, and (Table 2) .
Gastric Emptying
Estimates of paracetamol AUC 0-5 h were only significantly lower (17%) with liraglutide 1.2 mg, with no significant differences observed with liraglutide 0.6 mg (6%; P=0.287) or liraglutide 1.8 mg (6%; P=0.301). Compared with placebo, estimates of paracetamol AUC 0-1 h and C max were significantly lower (by 43% and 30% for AUC 0-1 h , and 31% and 23% for C max ) at the two higher liraglutide doses (1.2 and 1.8 mg, respectively), indicating a delay in gastric emptying with liraglutide during the early phase after the breakfast meal (Table 3 ). There was no significant delay with liraglutide 0.6 mg. 
Exploratory Analysis Between Glucose and
Gastric Emptying
A positive association between glucose iAUC 0-1 h and paracetamol log (AUC 0-1 h ) was seen regardless of treatment (placebo/liraglutide); that is, the more the paracetamol response was reduced, the more glucose response was also reduced. Furthermore, for any given The decrease in PPG was likely to be driven by two mechanisms. Firstly, the glucose- small intestine is the rate-limiting step for glucose absorption and, therefore, is an important factor in determining PPG excursions. 40 In this study, it was observed that for any given gastric emptying rate, incremental PPG levels were reduced with liraglutide treatment compared with placebo.
Together with the fact that the glucose-lowering effect of liraglutide was still significant after adjusting for the effect of gastric emptying, this suggests that gastric emptying accounts for part, but not all, of the glucose-lowering effect of liraglutide.
In this study, the paracetamol absorption method was chosen to determine the rate of gastric emptying. ~2.4 h), deceleration of gastric emptying and improvements in postprandial glycemia with twice-daily exenatide are most pronounced at the meals before which exenatide has been given. 51, 52 In contrast, treatment with once-daily liraglutide enhanced. Glucose-dependent insulin secretion therefore appears to be an important mechanism for reduction of both FPG and PPG levels. This is most likely explained by the ability of liraglutide to restore the incretin response, which is partially lost in patients with type 2 diabetes.
55
In contrast to the findings in the present study with liraglutide, the postprandial insulin response with exenatide was reduced compared with placebo, suggesting that delayed gastric emptying plays a substantial role in the improvement of PPG after exenatide.
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Exenatide should be dosed twice-daily within 60 minutes prior to two major meals of the day, and improves postprandial glycemic control of these meals. 52, 56 Due to a longer t 1/2 , liraglutide exposure covers 24 hours and can be administered once-daily, independent of meal times.
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In this study, liraglutide was well tolerated.
No hypoglycemic events were reported, which is in line with the glucose-dependent insulinotropic effect of liraglutide. The AE profiles were comparable to placebo. There were no withdrawals from treatment and no safety concerns were raised. 
CONCLUSION
